RxDoctor Payments Data

Debra Kosko

Acute Care · Rochester, NYNPI 1275588097

Payments from drug & device makers

$889in general payments, 2019–2025

Across 38 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$263
  • Johnson & Johnson$251
  • Pfizer$59
  • Daiichi Sankyo Inc.$53
  • Beone Medicines USA, Inc.$40
  • Tempus AI, Inc$30
  • plus $192 from 9 others

What the payments were for

  • Food & beverage$889100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$889 in reported general payments places this provider in the 75th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$13,840
Medicare patients
93
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib31$443,921
IbrancePalbociclib24$363,881
RevlimidLenalidomide19$335,882
ImbruvicaIbrutinib15$199,278
NubeqaDarolutamide12$154,308
Abiraterone Acetate31$91,301
Imatinib Mesylate16$58,895
EliquisApixaban65$54,295
LonsurfTrifluridine/Tipiracil Hcl11$48,668
XareltoRivaroxaban11$12,635
Exemestane17$2,418
Anastrozole65$1,004
Letrozole40$850
Hydroxyurea34$829
Acyclovir30$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$28$443,92131 claims
PfizerIbrance, Eliquis$59$418,17689 claims
Bristol Myers SquibbRevlimid$21$335,88219 claims
Johnson & JohnsonXarelto$251$12,63511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 980 acute care providers in New York.

Other acute care in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →